---
title: "10X Genomics Inc reports results for the quarter ended December 31 - Earnings Summary"
date: "2025-02-13 06:41:01"
summary: "10X Genomics Inc reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 29 cents..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* 10X Genomics Inc reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -38 cents to -14 cents per share.
* Revenue fell 10.3% to $165.02 million from a year ago; analysts expected $159.39 million.
* 10X Genomics Inc's reported EPS for the quarter was a loss of 40 cents​.
* The company reported a quarterly loss of $49.03 million.
* 10X Genomics Inc shares had fallen by 17.7% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 2.1% in the last three months.​
* In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 10 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc is $20.00

This summary was machine generated from LSEG data February 12 at 10:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact [RefinitivNewsSupport@thomsonreuters.com](http://mailto:RefinitivNewsSupport@thomsonreuters.com))

| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| --- | --- | --- | --- |
| Dec. 31 2024 | -0.29 | -0.40 | Missed |
| Sep. 30 2024 | -0.34 | -0.30 | Beat |
| Jun. 30 2024 | -0.48 | -0.32 | Beat |
| Mar. 31 2024 | -0.50 | -0.50 | Met |

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3P32OH:0-10x-genomics-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
